Persistent Asset Partners Ltd Acquires New Position in Replimune Group, Inc. $REPL

Persistent Asset Partners Ltd acquired a new stake in Replimune Group, Inc. (NASDAQ:REPL) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 61,488 shares of the company’s stock, valued at approximately $598,000. Persistent Asset Partners Ltd owned 0.07% of Replimune Group as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Squarepoint Ops LLC lifted its stake in shares of Replimune Group by 22.3% in the fourth quarter. Squarepoint Ops LLC now owns 67,271 shares of the company’s stock valued at $654,000 after purchasing an additional 12,264 shares during the period. Entropy Technologies LP acquired a new stake in shares of Replimune Group in the fourth quarter valued at about $102,000. Marshall Wace LLP acquired a new stake in shares of Replimune Group in the fourth quarter valued at about $910,000. Hudson Bay Capital Management LP acquired a new stake in shares of Replimune Group in the fourth quarter valued at about $1,493,000. Finally, Rafferty Asset Management LLC lifted its stake in shares of Replimune Group by 29.8% in the fourth quarter. Rafferty Asset Management LLC now owns 140,909 shares of the company’s stock valued at $1,370,000 after purchasing an additional 32,317 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Stock Performance

NASDAQ:REPL opened at $8.78 on Wednesday. The firm has a 50 day simple moving average of $5.27 and a 200-day simple moving average of $7.25. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The firm has a market cap of $724.99 million, a PE ratio of -2.55 and a beta of 0.88. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $13.24.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. BMO Capital Markets cut shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research report on Monday, April 13th. Leerink Partners restated a “market perform” rating and set a $2.00 target price (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. Wedbush lifted their target price on shares of Replimune Group from $2.00 to $6.00 and gave the stock a “neutral” rating in a research report on Monday, June 1st. JPMorgan Chase & Co. upgraded shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $8.00 target price for the company in a research report on Friday, May 29th. Finally, Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a research report on Friday, April 10th. Seven analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $4.88.

Insider Buying and Selling at Replimune Group

In other news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the transaction, the insider owned 180,962 shares of the company’s stock, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.